Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EPS (Weighted Average and Diluted) (2023 - 2025)

BioNexus Gene Lab's EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.4 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 51.29% year-over-year to -$0.4; the TTM value through Sep 2025 reached -$0.16, up 68.56%, while the annual FY2024 figure was -$0.09, 45.78% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.4 at BioNexus Gene Lab, down from -$0.34 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.61 in Q4 2024 and bottomed at -$0.81 in Q3 2024.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.02 (2024), against an average of -$0.11.
  • The largest annual shift saw EPS (Weighted Average and Diluted) surged 2673.01% in 2024 before it plummeted 483.33% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $0.02 in 2023, then soared by 2673.01% to $0.61 in 2024, then crashed by 164.33% to -$0.4 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's EPS (Weighted Average and Diluted) are -$0.4 (Q3 2025), -$0.34 (Q2 2025), and -$0.04 (Q1 2025).